Dr. Reddy's semaglutide pen production halted; FY27 supply target slashed to 6-7 mn
Emergency call: API impurity found in validation batches; commercial supply now expected from November, with supply target cut from 12 million to 6-7 million pens.
What's new
- Emergency concall: semaglutide API scale-up failed validation due to out-of-spec impurity.
- Commercial supply resumption expected November; validation complete by end-September.
- FY27 semaglutide supply target revised to 6-7 million pens from 12 million.
- No patient safety impact; no recall; inventory write-down likely immaterial.
Themes from the call
Demand
Semaglutide demand remains strong, exceeding industry supply; management says could sell 15 million pens annually if successful.
Margins
FY27 EBITDA margin target of 25%+ unchanged, but temporary hit from 3-month supply gap and potential write-down.
Capital allocation
Captive fill-finish facility timeline extended by several months due to validation delays; backup supplier qualification ~1 year away.
Guidance watch
- Validation completion by end-September, commercial supply in October to One Source, November to market.
- FY27 semaglutide supply: 6-7 million pens in Q3-Q4 (November-March window).
- Long-term EBITDA margin target of 25%+ unchanged.
Risk flags
- Execution risk on 3-month resolution timeline; management acknowledged failure possible.
- Inventory write-down amount unknown; to be disclosed with Q1 results in two weeks.
- Distribution partners may shift towards alternatives; some already made other arrangements.
Key quotes
-
"We cannot supply a product to the market that is not validated. It is a matter of safety and GMP, not cost."
— Erez Israeli, CEO -
"We could supply 15 million pens annually if scale-up successful."
— Management
The brief
Dr. Reddy's held an emergency concall this week to disclose that its semaglutide API scale-up hit a quality wall. An impurity emerged during formulation, rendering validation batches out of spec. No product reached patients, no recall is needed, but the commercial supply timeline has been pushed out by three months. Management now expects validation by end-September, commercial supply to partner One Source in October, and market availability from November. The FY27 supply target has been cut from 12 million pens to 6-7 million, all in Q3-Q4. The underlying demand story remains intact. Semaglutide is supply-constrained globally, and Dr. Reddy's believes it could sell 15 million pens annually once the process is stable. The quality-first decision protects long-term trust but comes with a near-term cost: roughly 3 million pens of lost contribution margin, plus a probable inventory write-down on the failed batches. The exact financial hit will be disclosed with Q1 results in two weeks. Long-term guidance — 25%+ EBITDA margins, captive fill-finish facility, One Source partnership — is unchanged. The three-month fix is credible but not guaranteed. Management acknowledged execution risk. Investors now watch two things: the September validation milestone and the Q1 disclosure. Both will determine whether this is a temporary setback or a credibility test.
Dr. Reddy's quality-first stance protects long-term credibility, but the near-term semaglutide revenue hole is real and the clock is ticking on the 3-month fix.